PGEN stock forecast, quote, news & analysis
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms... Show more
Why Precigen (PGEN) Stock Is Down -41% in the Last 30 Days
Key Takeaways
- Precigen shares fell roughly 41% over the last 30 days, from about $8.54 to around $5.08, driven primarily by new competition in its core market.
- The key catalyst was the FDA's accelerated approval of Inovio's (INO) Voceryq, a rival therapy for recurrent respiratory papillomatosis (RRP).
- The stock rallied to a 52-week high of $8.98 in late September before reversing through October and collapsing in after-hours trading on October 30.
- PAPZIMEOS, Precigen's only approved product, accounts for the overwhelming majority of the company's revenue and is now facing its first direct competitor.
- Third-quarter 2026 financial results are scheduled for November 4, with analysts projecting another quarter of strong top-line growth.
- For more detail on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots for AI-driven trading insights across thousands of tickers.
Precigen (PGEN) Company Overview and Market Position
Precigen, Inc. is a commercial-stage biopharmaceutical company headquartered in Germantown, Maryland, that develops gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. The company, formerly known as Intrexon, was renamed in February 2020. Its proprietary platforms include the AdenoVerse immunotherapy platform, the UltraCAR-T cell therapy platform, and the UltraPorator electroporation device used to manufacture therapies at the point of care.
Precigen's commercial story centers on PAPZIMEOS, the first FDA-approved therapy for adult recurrent respiratory papillomatosis (RRP), cleared in August 2025. The product launched commercially in late 2025 and generated $53.1 million in net product revenue in the second quarter of 2026, roughly doubling the prior quarter. Investors closely follow the stock because PAPZIMEOS has been effectively the company's entire revenue story, while the broader AdenoVerse pipeline, including PRGN-2009 in HPV-associated cancers, represents the longer-term growth narrative.
Precigen (PGEN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PGEN declined approximately 41%, falling from a closing price of $8.54 on October 2 to roughly $5.08 in early November trading. The decline accelerated sharply in after-hours trading on October 30, when the shares dropped about 27% following a major competitive development.
The quarterly picture is more nuanced. Precigen climbed from the low-$6 range in early August to a 52-week high of $8.98 on September 30, extending a strong 2026 rally. That advance then reversed: the stock pulled back through October and, after the late-October selloff, ended the trailing three-month period down roughly 19% from where it began, despite its earlier strength. The result is a quarter defined by a sharp rally followed by an equally sharp reversal.
What Drove PGEN Stock Price in the Last 30 Days
The dominant catalyst was regulatory. On October 30, the U.S. Food and Drug Administration granted accelerated approval to Inovio Pharmaceuticals' Voceryq, a plasmid DNA-based immunotherapy for adults with RRP, the same rare disease treated by Precigen's PAPZIMEOS. Because PAPZIMEOS had been the only FDA-approved therapy in that market, investors had priced Precigen partly as a company with an unrivaled standard of care. The approval of a direct competitor removed that exclusivity premium, sending PGEN down roughly 27% in after-hours trading while Inovio's shares surged.
The selloff was amplified by the stock's technical position. PGEN had already been rolling over before the news, falling about 19% in October from its late-September high. The after-hours decline took the stock toward long-term support near its 200-day moving average, reinforcing the downward momentum. The pre-earnings timing also mattered: with third-quarter results due November 4, traders reassessed the company's valuation just as it faces new competition in its core market.
What Drove PGEN Stock Performance Over the Last Quarter
The broader quarterly trend reflected a powerful commercial ramp followed by a competitive shock. Through the third quarter, Precigen benefited from the rapid launch of PAPZIMEOS, which posted $74.7 million in net product revenue in the first half of 2026 and helped the company achieve quarterly profitability. Positive analyst coverage, including Buy initiations from B. Riley Securities and H.C. Wainwright, and an FDA platform technology designation for AdenoVerse in September supported sentiment, pushing the stock to its 52-week high.
That momentum faded as the market began discounting the risk of competition. The arrival of Inovio's approved rival reversed the single-product exclusivity thesis that had underpinned much of the 2026 advance, and the late-quarter collapse wiped out most of the quarter's earlier gains. The result was a period of extreme volatility in which fundamentals strengthened but the stock's risk profile changed materially.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots are featured in the curated Trending AI Robots section. These bots vary in strategy, trading timeframe, and performance metrics, giving traders a range of systematic approaches to explore. The section highlights the bots that are currently drawing the most attention, offering a useful starting point for investors who want to see how AI-driven strategies are navigating shifting market conditions. Traders and investors interested in automated, data-driven signals can review the page to evaluate which bots align with their own objectives.
PGEN Stock Forecast Drivers: What Investors Should Watch Next
Investors should focus on several near-term factors. First, Precigen's third-quarter 2026 earnings release on November 4 will provide a critical read on PAPZIMEOS revenue momentum and any early commentary on competitive dynamics following the Inovio approval. Analysts have projected roughly $71 million in quarterly revenue, up sequentially from the second quarter. Second, the pace of Inovio's commercial launch—with shipments expected within about 60 days—will shape how quickly competition affects Precigen's market share. Third, updates on the AdenoVerse pipeline, including PRGN-2009 in HPV-associated cancers and the expected year-end portfolio update, will indicate whether Precigen can diversify beyond a single product. Finally, broader biotech sentiment, macro conditions, and any further analyst rating changes will remain relevant to the stock's direction. These are informational considerations, not investment recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PGEN's Stochastic Oscillator is remaining in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PGEN's RSI Oscillator exited the oversold zone, 24 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +12.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in 206 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
PGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PGEN as a result. In 80 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for PGEN turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 47 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
PGEN moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PGEN crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PGEN entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (36.727) is normal, around the industry mean (3.498). P/E Ratio (-4.178) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (32.258) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How Do Embargoes Impact Global Trade and Diplomacy?
What is negative correlation, and how is it different from positive correlation?
What are the awards for the best online brokers called?
What Is Make to Order (MTO) Production Strategy?
Best 3 AI Trading Robots: Navigating Market Volatility with Advanced Strategies
General Information
a biotechnology company, which engages in the research and development of synthetic biology technologies.
Industry Biotechnology